Review Article | Published:

The metabolic actions of glucagon revisited

Nature Reviews Endocrinology volume 6, pages 689697 (2010) | Download Citation

Abstract

The initial identification of glucagon as a counter-regulatory hormone to insulin revealed this hormone to be of largely singular physiological and pharmacological purpose. Glucagon agonism, however, has also been shown to exert effects on lipid metabolism, energy balance, body adipose tissue mass and food intake. The ability of glucagon to stimulate energy expenditure, along with its hypolipidemic and satiating effects, in particular, make this hormone an attractive pharmaceutical agent for the treatment of dyslipidemia and obesity. Studies that describe novel preclinical applications of glucagon, alone and in concert with glucagon-like peptide 1 agonism, have revealed potential benefits of glucagon agonism in the treatment of the metabolic syndrome. Collectively, these observations challenge us to thoroughly investigate the physiology and therapeutic potential of insulin's long-known opponent.

Key points

  • In addition to its well-known effects on glycemia, increased glucagon signaling directly regulates triglyceride, free fatty acid, apolipoprotein and bile acid metabolism

  • Glucagon action can be inhibited via receptor desensitization by excess dietary fat intake

  • Energy expenditure and thermogenesis are increased by glucagon agonism

  • Glucagon administration stimulates satiety and decreases food intake

  • Glucagon action, in combination with incretins such as glucagon-like peptide 1, may be a crucial tool in the treatment of the metabolic syndrome

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The internal secretion of the pancreas. J. Lab. Clin. Med. 7, 251–266 (1922).

  2. 2.

    , , & Aqueous extracts of the pancreas. I. Influence on the carbohydrate metabolism of depancreatized animals. J. Biol. Chem. 56, 253–296 (1923).

  3. 3.

    & The role of cyclic AMP in the control of liver metabolism. Adv. Enzyme Regul. 6, 391–407 (1968).

  4. 4.

    , & Cyclic AMP. Annu. Rev. Biochem. 37, 149–174 (1968).

  5. 5.

    et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Ther. 331, 871–881 (2009).

  6. 6.

    et al. Leptin therapy in insulin-deficient type I diabetes. Proc. Natl Acad. Sci. USA 107, 4813–4819 (2010).

  7. 7.

    , & Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31, 1403–1404 (2008).

  8. 8.

    & The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 28, 253–283 (2007).

  9. 9.

    , & Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28, 84–116 (2007).

  10. 10.

    et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749–757 (2009).

  11. 11.

    et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258–2266 (2009).

  12. 12.

    & Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007).

  13. 13.

    , & Heterodimeric Pbx-Prep1 homeodomain protein binding to the glucagon gene restricting transcription in a cell type-dependent manner. J. Biol. Chem. 275, 27989–27999 (2000).

  14. 14.

    et al. Protein hydrolysates stimulate proglucagon gene transcription in intestinal endocrine cells via two elements related to cyclic AMP response element. Diabetologia 47, 926–936 (2004).

  15. 15.

    , & TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J. Biol. Chem. 280, 1457–1464 (2005).

  16. 16.

    Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc. Natl Acad. Sci. USA 88, 7224–7227 (1991).

  17. 17.

    et al. MafB: an activator of the glucagon gene expressed in developing islet alpha- and beta-cells. Diabetes 55, 297–304 (2006).

  18. 18.

    et al. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 149, 2341–2351 (2008).

  19. 19.

    , & Different metabolic responses in alpha-, beta-, and delta-cells of the islet of Langerhans monitored by redox confocal microscopy. Biophys. J. 90, 2641–2650 (2006).

  20. 20.

    et al. Adrenaline stimulates glucagon secretion in pancreatic A-cells by increasing the Ca2+ current and the number of granules close to the L-type Ca2+ channels. J. Gen. Physiol. 110, 217–228 (1997).

  21. 21.

    et al. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 5, e143 (2007).

  22. 22.

    , , , & Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54, 1808–1815 (2005).

  23. 23.

    et al. Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146, 4861–4870 (2005).

  24. 24.

    & Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54, 1789–1797 (2005).

  25. 25.

    & Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 32, 2275–2280 (2009).

  26. 26.

    , & Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48, 1700–1713 (2005).

  27. 27.

    , , , & Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 55, 1051–1056 (2006).

  28. 28.

    et al. Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53, 1443–1448 (2004).

  29. 29.

    Autonomic regulation of islet hormone secretion—implications for health and disease. Diabetologia 43, 393–410 (2000).

  30. 30.

    et al. Glucose regulates proinsulin and prosomatostatin but not proglucagon messenger ribonucleic acid levels in rat pancreatic islets. Endocrinology 141, 174–180 (2000).

  31. 31.

    et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167–194 (2003).

  32. 32.

    , , & Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol. Cell Endocrinol. 105, 131–137 (1994).

  33. 33.

    , , & Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Mol. Cell Endocrinol. 311, 69–76 (2009).

  34. 34.

    , & Glucagon receptors in endothelial and Kupffer cells of mouse liver. J. Histochem. Cytochem. 36, 1081–1089 (1988).

  35. 35.

    , , , & Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137, 5119–5125 (1996).

  36. 36.

    , , & Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43, 1012–1019 (2000).

  37. 37.

    et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl Acad. Sci. USA 100, 1438–1443 (2003).

  38. 38.

    et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50, 142–150 (2007).

  39. 39.

    et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55, 3463–3469 (2006).

  40. 40.

    et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 297, E695–E707 (2009).

  41. 41.

    et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl Acad. Sci. USA 100, 6825–6830 (2003).

  42. 42.

    et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52, 741–750 (2003).

  43. 43.

    , , & The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J. Biol. Chem. 246, 1877–1882 (1971).

  44. 44.

    The complex regulation of receptor-coupled G-proteins. Adv. Enzyme Regul. 37, 427–435 (1997).

  45. 45.

    et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 259, 1614–1616 (1993).

  46. 46.

    et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109–1111 (2005).

  47. 47.

    et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131–138 (2001).

  48. 48.

    et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183 (2001).

  49. 49.

    , & Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase. J. Biol. Chem. 279, 54103–54109 (2004).

  50. 50.

    , , , & Effects of ethanol on mitogen-activated protein kinase and stress-activated protein kinase cascades in normal and regenerating liver. Biochem. J. 334 (Pt 3), 669–676 (1998).

  51. 51.

    & Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671–E678 (2003).

  52. 52.

    et al. Glucagon effects on ischemic vasodilatation in the isolated rat heart. J. Biomed. Biotechnol. 2010, 231832 (2010).

  53. 53.

    & Glucagon and cholesterol metabolism. Metabolism 9, 938–945 (1960).

  54. 54.

    , , & Metabolic effects of glucagon in human subjects. Metabolism 9, 753–768 (1960).

  55. 55.

    & Jr. Glucagon as a regulating factor of plasma lipids. Metabolism 10, 315–323 (1961).

  56. 56.

    , & Effect of glucagon on the serum lipids in essential hyperlipemia and in hypercholesterolemia. Metabolism 11, 1240–1249 (1962).

  57. 57.

    , , & Role of glucagon on fatty liver production in birds. Am. J. Physiol. 221, 25–30 (1971).

  58. 58.

    & Transfer of plasma lipid to platelets by action of glucagon. Metabolism 19, 598–607 (1970).

  59. 59.

    & Glucagon and plasma arachidonic acid. Metabolism 14, 684–692 (1965).

  60. 60.

    , & Suppression by hepatectomy of glucagon-induced hypertriglyceridemia in geese. Proc. Soc. Exp. Biol. Med. 136, 107–110 (1971).

  61. 61.

    , & The effects of glucagon, dibutyryl cyclic adenosine 3',5'-monophosphate, and concentration of free fatty acid on hepatic lipid metabolism. J. Biol. Chem. 244, 5131–5139 (1969).

  62. 62.

    , , , & Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver. Diabetes 15, 740–748 (1966).

  63. 63.

    Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res. 14, 312–318 (1973).

  64. 64.

    , Mathé, D., & Effects of chronic glucagon administration on cholesterol and bile acid metabolism. Biochim. Biophys. Acta 963, 215–223 (1988).

  65. 65.

    , Mathé, D., & Effects of chronic glucagon administration on rat lipoprotein composition. Biochim. Biophys. Acta 1005, 233–238 (1989).

  66. 66.

    et al. Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats. Lipids 26, 451–458 (1991).

  67. 67.

    , , , & Effect of chronic glucagon administration on the metabolism of triacylglycerol-rich lipoproteins in rats fed a high sucrose diet. J. Nutr. 121, 24–30 (1991).

  68. 68.

    & Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo. J. Clin. Invest. 91, 2796–2805 (1993).

  69. 69.

    , , & Effects of exogenous glucagon on lipids in lipoproteins and liver of lactating dairy cows. J. Dairy Sci. 86, 2895–2903 (2003).

  70. 70.

    , , , & Metabolic responses of lactating dairy cows to single and multiple subcutaneous injections of glucagon. J. Dairy Sci. 86, 2072–2081 (2003).

  71. 71.

    et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8, 359–371 (2008).

  72. 72.

    , & Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides 10, 333–335 (1989).

  73. 73.

    , & Effects of denervation on the metabolism and the response to glucagon of white adipose tissue of rats. Horm. Metab. Res. 5, 245–250 (1973).

  74. 74.

    , , , & Physiological effect of glucagon in human isolated adipocytes. Horm. Metab. Res. 27, 372–375 (1995).

  75. 75.

    , , & Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans. J. Clin. Invest. 82, 198–205 (1988).

  76. 76.

    et al. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N. Engl. J. Med. 292, 985–989 (1975).

  77. 77.

    et al. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment. Biochem. J. 264, 93–100 (1989).

  78. 78.

    , , , & Evidence that the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA is an important site of regulation of hepatic fatty acid oxidation in the fetal and newborn rabbit. Perinatal development and effects of pancreatic hormones in cultured rabbit hepatocytes. Biochem. J. 269, 409–415 (1990).

  79. 79.

    et al. Regulation of fatty-acid metabolism by pancreatic hormones in cultured human hepatocytes. Hepatology 13, 1126–1130 (1991).

  80. 80.

    , , & Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int. J. Sports Med. 26, 432–441 (2005).

  81. 81.

    , & High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J. Physiol. 579 (Pt 1), 255–267 (2007).

  82. 82.

    , , & Alterations in hepatic glucagon receptor density and in Gsalpha and Gialpha2 protein content with diet-induced hepatic steatosis: effects of acute exercise. Am. J. Physiol. Endocrinol. Metab. 289, E8–E14 (2005).

  83. 83.

    , & A role for protein kinase C-mediated phosphorylation in eliciting glucagon desensitization in rat hepatocytes. Biochem. J. 307 (Pt 1), 281–285 (1995).

  84. 84.

    & Glucagon resistance as a hormonal basis for endogenous hyperlipaemia. Lancet 1, 973–974 (1973).

  85. 85.

    & Glucagon and cAMP inhibit cholesterol 7alpha-hydroxylase (CYP7A1) gene expression in human hepatocytes: discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology 43, 117–125 (2006).

  86. 86.

    Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23, 443–463 (2002).

  87. 87.

    et al. Hormonal regulation of cholesterol 7 alpha-hydroxylase mRNA levels and transcriptional activity in primary rat hepatocyte cultures. J. Biol. Chem. 267, 16866–16871 (1992).

  88. 88.

    , & The effect of glucagon on the metabolic rate of rats. Am. J. Clin. Nutr. 8, 540–546 (1960).

  89. 89.

    , & Calorigenic action of glucagon. Nature 180, 1124 (1957).

  90. 90.

    Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J. Clin. Endocrinol. Metab. 64, 896–901 (1987).

  91. 91.

    Insulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man. Metabolism 43, 1000–1005 (1994).

  92. 92.

    Stimulation of metabolism of rat brown adipose tissue by addition of lipolytic hormones in vitro. J. Biol. Chem. 241, 814–821 (1966).

  93. 93.

    & Thermogenic responses of brown adipocytes to noradrenaline and glucagon in heat-acclimated and cold-acclimated rats. Jpn. J. Physiol. 29, 683–690 (1979).

  94. 94.

    , & Effects of glucagon and noradrenaline on the blood flow through brown adipose tissue in temperature-acclimated rats. Jpn. J. Physiol. 33, 367–376 (1983).

  95. 95.

    & Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats. Life Sci. 30, 785–791 (1982).

  96. 96.

    , , & Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am. J. Physiol. 261 (Pt 2), R501–R507 (1991).

  97. 97.

    & Adaptive changes in insulin and glucagon secretion during cold acclimation in the rat. Am. J. Physiol. 250 (Pt 1), E669–E676 (1986).

  98. 98.

    , , , & Glucagon stimulation of brown adipose tissue growth and thermogenesis. Am. J. Physiol. 252 (Pt 2), R160–R165 (1987).

  99. 99.

    et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509–1517 (2009).

  100. 100.

    , , & Apparent thermogenic effect of injected glucagon is not due to a direct effect on brown fat cells. Am. J. Physiol. 275 (Pt 2), R1674–R1682 (1998).

  101. 101.

    & The effect of propranalol on the calorigenic response in brown adipose tissue of new-born rabbits to catecholamines, glucagon, corticotrophin and cold exposure. J. Physiol. 187, 271–283 (1966).

  102. 102.

    et al. Role of catecholamines in glucagon-induced thermogenesis. J. Neural Transm. 112, 481–489 (2005).

  103. 103.

    et al. Sympathetic control of glucagon receptor mRNA levels in brown adipose tissue of cold-exposed rats. Mol. Cell Biochem. 208, 139–142 (2000).

  104. 104.

    , & Differential sympathetic drive to adipose tissues after food deprivation, cold exposure or glucoprivation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R1445–R1452 (2008).

  105. 105.

    , , , & Effect of diet and cold exposure on norepinephrine turnover in brown adipose tissue of the rat. J. Clin. Invest. 69, 1061–1071 (1982).

  106. 106.

    , & The mechanism of satiety: effect of glucagon on gastric hunger contractions in man. Proc. Soc. Exp. Biol. Med. 89, 258–261 (1955).

  107. 107.

    , , & Effect of glucagon on food intake and body weight in man. J. Appl. Physiol. 11, 419–421 (1957).

  108. 108.

    & Jr. Depression of food intake induced in healthy subjects by glucagon. N. Engl. J. Med. 264, 893–897 (1961).

  109. 109.

    & Decreased feeding in rats following hepatic-portal infusion of glucagon. Physiol. Behav. 19, 461–466 (1977).

  110. 110.

    & Dose-related suppression of feeding by intraportal glucagon infusion in the rat. Am. J. Physiol. 250 (Pt 2), R676–R681 (1986).

  111. 111.

    Metabolic effects of glucagon in the Wistar rat. Am. J. Clin. Nutr. 8, 535–539 (1960).

  112. 112.

    & Effect of glucagon on food intake and weight gain in the young rat. Can. J. Physiol. Pharmacol. 42, 867–869 (1964).

  113. 113.

    & Hepatic portal glucagon infusion decreases spontaneous meal size in rats. Am. J. Physiol. 261 (Pt 2), R154–R161 (1991).

  114. 114.

    , & Hypothalamic influence on insulin and glucagon release in the rat. Am. J. Physiol. 233, E380–E388 (1977).

  115. 115.

    , , , & Hepatic handling of pancreatic glucagon and glucose during meals in rats. Am. J. Physiol. 247 (Pt 2), R827–R832 (1984).

  116. 116.

    & Physiology and pathophysiology of glucagon. Physiol. Rev. 56, 778–826 (1976).

  117. 117.

    , & Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats. Am. J. Physiol. 261 (Pt 2), R162–R165 (1991).

  118. 118.

    , , & Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 218, 894–896 (1982).

  119. 119.

    , , & Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am. J. Physiol. 262 (Pt 2), R975–R980 (1992).

  120. 120.

    , & Glucagon acts in the liver to control spontaneous meal size in rats. Am. J. Physiol. 264 (Pt 2), R116–R122 (1993).

  121. 121.

    , & Loss of glucagon suppression of feeding after vagotomy in rats. Am. J. Physiol. 234, E314–E318 (1978).

  122. 122.

    & Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect. Physiol. Behav. 31, 391–394 (1983).

  123. 123.

    et al. Effects of central administration of glucagon on feed intake and endocrine responses in sheep. Anim. Sci. J. 80, 686–690 (2009).

  124. 124.

    , , & Potential treatment of fatty liver with 14-day subcutaneous injections of glucagon. J. Dairy Sci. 86, 3138–3147 (2003).

Download references

Author information

Affiliations

  1. Department of Medicine, University of Cincinnati, Metabolic Diseases Institute, Office E-217, 2170 East Galbraith Road, Cincinnati, OH 45237, USA

    • Kirk M. Habegger
    • , Kristy M. Heppner
    •  & Matthias H. Tschöp
  2.  Institute of Food, Nutrition and Health, Swiss Federal Institute of Technology Zürich, Schorenstraße 16, 8603 Schwerzenbach, Switzerland

    • Nori Geary
  3.  Department of Biology, Georgia State University, 33 Gilmer Street Southeast, Atlanta, GA 30303-3044, USA

    • Timothy J. Bartness
  4.  Department of Chemistry, Indiana University, 107 South Indiana Avenue, Bloomington, IN 47405-7000, USA

    • Richard DiMarchi

Authors

  1. Search for Kirk M. Habegger in:

  2. Search for Kristy M. Heppner in:

  3. Search for Nori Geary in:

  4. Search for Timothy J. Bartness in:

  5. Search for Richard DiMarchi in:

  6. Search for Matthias H. Tschöp in:

Contributions

All authors researched the data for the article, provided a substantial contribution to discussions of the content, contributed equally to writing the article and reviewed and/or edited the manuscript before submission.

Competing interests

N. Geary declares an association with the following company: Novo Nordisk (consultant). R. DiMarchi declares an association with the following company: Marcadia Biotech (stockholder/director). The other authors declare no competing interests.

Corresponding author

Correspondence to Matthias H. Tschöp.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2010.187